甲状旁腺切除术纠正继发性甲状旁腺功能亢进改善肾性贫血的临床研究
Department of Nephrology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China
-
摘要: 目的 探讨甲状旁腺切除术(PTX)纠正重度继发性甲状旁腺功能亢进(SHPT)对难治性肾性贫血的影响。方法 选取并发重度SHPT及难治性肾性贫血的维持性血液透析(MHD)患者33例，均为药物治疗无效后行PTX。观察术前、术后第1、3、6、12个月时患者血清全段甲状旁腺激素(iPTH)、钙(Ca)、磷(P)、血红蛋白(Hb)及红细胞压积(Hct)、重组人促红细胞生成素(rHuEPO)用量、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)、血清白蛋白(ALB)、C反应蛋白(CRP)及Kt/V等指标的变化情况。结果 与术前相化，PTX术后1月血清iPTH、Ca、P显著下降(PPPP>0.05)。结论 采用PTX纠正SHPT可显著改善MHD患者的肾性贫血，同时改善rHuEPO抵抗，提示重度SHPT是影响肾性贫血及rHuEPO疗效的一个重要因素。
-
关键词:
- 继发性甲状旁腺功能亢进 /
- 肾性贫血 /
- 甲状旁腺切除术
Abstract: Objective To evaluate the effects of parathyroidectomy (PTX) on renal anemia in maintenance hemodialysis (MHD) patients with severe secondary hyperparathyroidism (SHPT). Methods Thirty-three MHD patients with severe SHPT were enrolled，all these patients were underwent PTX after failure of medical therapy. The iPTH, Ca, P and anemia levels, iron homeostasis, dose of rHuEPO requirement and nutritional state were assessed before and 1,3,6,12 months after PTX, and Kt/V were calculated. Results The levels of iPTH, Ca, P were decreased significantly from 1 month after PTX. The hemoglobin level and hematocrit showed a significant increase at 3 months after PTX, and rHuEPO dose requirement decreased remarkablely from 6 months after PTX. There was no statistically significant difference in serum iron and transferrin saturation, CRP, and the adequacy of dialysis before and after PTX. Conclusion We conclude that PTX can improve renal anemia and decrease the resistance to rHuEPO therapy at the same time in MHD patients with severe SHPT.-
Keywords:
- secondary hyperparathyroidism /
- renal anemia /
- parathyroidectomy
-
-
[1] Tilman Druoke. Hyporesponsiveness to recombinant human erythropoietin [J]. Nephrol Dial Transplant, 2001,16(suppl7): 25-28.
[2] 姚力,张凌,刘鹏,等.甲状旁腺切除术治疗难治性甲状旁腺功能亢进症89例疗效评价[J]. 中国血液净化, 2009,8(8)：431-436.
[3] Stephen J Marx. Hyperparathyroid and Hypoparathyroid Disorders [J]. N Engl J Med, 2000,343:1863-1875.
[4] Nikodimopoulou M, Liakos S. Secondary hyperparathyroidism and target organs in chronic kidney disease [J]. Hippokratia，2011, 15 (Suppl 1): 33-38.
[5] Kause AT, Solid C, Perira BJ, et al. Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease? [J]. Am J Kidney Dis, 2005, 45(1): 136-147.
[6] Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia [J]. N Engl J Med, 1993, 328(3): 171-175.
[7] Sikole A. Pathogenesis of anaemia in hyperparathyroidism [J].Med Hypotheses, 2000, 54(2): 236-238.
[8] Wu SG, Jeng FR, Wie SY, et al. Red blood cell osmotic fragility in chronically hemodialyzed patients [J]. Nephron,1998, 78: 28-32.
[9] Chow TL, Chan TT, Ho YW, et al. Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis [J]. Arch Surg,2007,142(7):644-648.
[10] Bhadada SK, Sridhar S, Ahluwalia J, et al. Anemia and thrombocytopenia improves after curative parathyroidectomy in a patient of primary hyperparathyroidism (PHPT) [J]. J Clin Endocrinol Metab,2012,97(5):1420-1422.
[11] Trunzo JA, McHenry CR, Schulak JA, et al. Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism [J]. Surgery,2008,144(6):915-918.
计量
- 文章访问数: 2165
- PDF下载数: 1281
- 施引文献: 0
下载:
